Introduction
============

Triple-negative breast cancer (TNBC) is a type of breast cancer (BC) in which the expression of human epidermal growth factor receptor 2 (HER2), progesterone receptor and oestrogen receptor have all been deleted ([@b1-or-44-03-0819]). TNBC is associated with distinct clinical characteristics and molecular complexity compared with other types of BCs ([@b1-or-44-03-0819]). Typically, prognosis for women with TNBC following metastatic recurrence is poorer compared with those with other subtypes of BCs ([@b2-or-44-03-0819]). Chemotherapy remains to be the preferred systemic treatment for TNBC ([@b3-or-44-03-0819]). Although subpopulations showing effective response to chemotherapy can be identified, particularly in those carrying BRCA1 mutations, the effectiveness of chemotherapy is restricted in other subpopulations with TNBC ([@b4-or-44-03-0819]). A number of treatment strategies have been previously developed for clinical intervention, including platinum salts, poly ADP-ribose polymerase inhibitors, immunological agents and mitogen-activated extracellular signal-regulated kinase inhibitors ([@b5-or-44-03-0819]--[@b7-or-44-03-0819]). Among these, although a number of predictive biomarkers, including O6-methylguanine DNA methyltransferase ([@b8-or-44-03-0819]), isocitrate dehydrogenase ([@b9-or-44-03-0819]), epidermal growth factor receptor ([@b10-or-44-03-0819]) and phosphatase and tensin homolog ([@b11-or-44-03-0819]), have been identified, though suitable molecular features for optimizing personalized treatment strategies for individual patients remain insufficient ([@b12-or-44-03-0819]).

Accumulating evidence has demonstrated high heterogeneity within TNBC tumors, which is one of the main causes of recurrence and resistance ([@b13-or-44-03-0819],[@b14-or-44-03-0819]). A number of previous studies have applied the use of gene expression profiles in classifying TNBCs, which can offer relevant clinical information ([@b15-or-44-03-0819],[@b16-or-44-03-0819]). For example, platinum-based chemotherapy can be used for patients carrying breast cancer (BRCA) 1 and BRCA2 mutations. Harano *et al* ([@b17-or-44-03-0819]) previously recognized six TNBC subtypes based on gene expression profiles, where the immunomodulatory subtype was frequently observed during processes involving immunocytes. In another study, Bonsang-Kitzis *et al* ([@b18-or-44-03-0819]) classified six TNBC subgroups on the basis of gene selection driven by the biological network, where two immunity clusters were included and a gene signature was constructed based on the stromal immune module. In addition, Burstein *et al* ([@b19-or-44-03-0819]) previously recognized four TNBC subtypes with high stability on the basis of mRNA expression and DNA genomic profile data: i) Mesenchymal; ii) luminal/androgen receptor; iii) basal-like immune activated; and iv) basal-like immune suppressed. Based on this classification, Burstein *et al* ([@b19-or-44-03-0819]) also proposed candidate treatment targets for the aforementioned subtypes. The TNBC classification strategies aforementioned have contributed to laying the foundations for developing targeted TNBC treatments.

The reprogramming of energy metabolism can serve as a hallmark in cancer physiology, making it possible for cancer cells to produce ATP whilst maintaining redox balance and macromolecular biosynthesis, processes that are necessary for cell proliferation, growth, migration, drug resistance and angiogenesis ([@b20-or-44-03-0819]). It has been previously suggested that a large number of cancer types divert their energy metabolism towards the glycolytic pathway, resulting in the excessive production of lactate even under normoxic conditions, in a phenomenon known as the Warburg effect ([@b21-or-44-03-0819],[@b22-or-44-03-0819]). Compared with non-malignant cells, cancer cells generally prefer incomplete and non-oxidative glucose metabolism ([@b22-or-44-03-0819]). Although glucose has been accepted as a major source of energy in tumor cells, there is growing consensus regarding the heterogeneity of metabolic phenotypes in tumors. A portion of cancer cells prefer glycolysis, whilst other tumor cell types can bias towards oxidative phosphorylation (OXPHOS) ([@b23-or-44-03-0819],[@b24-or-44-03-0819]). In addition, there is an increasing number of reports revealing the presence of metabolic symbiosis between oxidative and glycolytic cancer cells. For instance, pyruvate and lactate produced by glycolysis can be transferred and utilized to become substrates of the tricarboxylic acid cycle (TCA) and for ATP production by neighboring tumor cells ([@b25-or-44-03-0819]). Likewise, malignant cancer cells can absorb ketone bodies and free fatty acids generated through catabolic cells in their vicinity, thereby accelerating mitochondrial OXPHOS ([@b26-or-44-03-0819]). Glutamine has also been reported to be metabolized by cancer cells through the TCA cycle for energy production under hypoxic conditions or those under glucose deficiency ([@b27-or-44-03-0819]). Therefore, an extensive understanding of energy metabolism in different types of cancer cells can promote the development of novel therapeutic strategies.

Catabolic pathways have been previously reported to participate in energy metabolism in TNBC cells, which exhibit high OXPHOS rates and are not responsive to glycolytic inhibitors. Under normoxic conditions, TNBCs generally prefer OXPHOS to glycolysis, whilst under hypoxic conditions, TNBCs generally prefer glycolysis ([@b28-or-44-03-0819]). Tumor stem cells do not display glycolytic phenotypes compared with those of the differentiated progeny cells for TNBC ([@b29-or-44-03-0819],[@b30-or-44-03-0819]). Previous studies have indicated that fatty acids can also be utilized by TNBC cells as substrates for energy production ([@b31-or-44-03-0819],[@b32-or-44-03-0819]). Inhibiting the β-oxidation of fatty acids can reduce cancer cell proliferation in myc-overexpressing TNBC ([@b31-or-44-03-0819]). However, the association between the local metabolic state and its prognostic significance in patients with TNBC remain unknown at present.

The present study aimed to investigate the expression profiles of genes associated with energy metabolism, together with their clinical significance in patients with TNBC, based on data obtained from the gene expression omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Patients were divided into four groups based on differential gene expression patterns, where these four groups exhibited significant differences in terms of prognosis, immunological and molecular features. A signature based on energy metabolism was subsequently constructed to assess TNBC patient prognosis based on the TCGA dataset, which was then verified using the GEO dataset. This signature showed close association with patient survival, suggesting that it can be used as an independent prognostic factor. These findings revealed that the energy metabolic state is closely associated with the clinical prognosis of TNBC.

Materials and methods
=====================

### Pre-processing of initial sample information

In total, 1097 BC samples were collected from the TCGA database for analysis, from which 191 samples that were negative for 'HER2', 'progesterone' and 'estrogen receptor expression' were screened using the three key words. A total of 177 samples with disease free survival (DFS) \>30 days was then obtained from the 191 samples. In addition, two GEO datasets \[GSE58812 ([@b33-or-44-03-0819]) and GSE21653 ([@b34-or-44-03-0819])\] were extracted from NCBI database, which were then normalized according to the robust multichip average (RMA) method ([@b35-or-44-03-0819]). The GSE21653 dataset included 87 TNBC cases, whilst the GSE58812 dataset included 107 TNBC cases. Of note, 2 cases were excluded due to the lack of prognostic information in the GSE21653 dataset. Following series data preprocessing aforementioned, 369 samples, including 177 from the TCGA training set and 192 from the GEO validation set, were acquired for further analysis. Using following three keywords 'metabolism', 'TCA' and 'glycogen', the expression profiles of 594 genes associated with energy metabolism were extracted from the Reactome database ([@b36-or-44-03-0819]) based on the related metabolic pathways ([Table I](#tI-or-44-03-0819){ref-type="table"}). [Table II](#tII-or-44-03-0819){ref-type="table"} displays the sample clinicopathological features of the samples.

### NMF (Negative matrix factorization) clustering

NMF clustering was performed to identify stable sample clusters based on 50 iterations according to the Brunet method ([@b37-or-44-03-0819]) using genes associated with energy metabolism. In addition, the cluster number, represented by k, was set as 2--10, whilst the best cluster number was calculated based on the cluster cophenetic correlation and the observed consensus map. The mean silhouette width of the consensus membership matrix was determined using the 'NMF' function in the R package (version 3.5.3; <http://bioconductor.org/biocLite.R>). For every member, the lowest cluster number for each member was set as 10. Maftools v1.6.15 from the R package was used to analyze the gene mutation profiles within the TNBC case clusters. The tumor immune estimation resource (TIMER; <http://cistrome.shinyapps.io/timer/>) was applied to calculate the scores of immune cell infiltration within the TNBC clusters ([@b38-or-44-03-0819]).

### Identification of gene signature

Differentially expressed genes (DEGs) associated with energy metabolism in the TCGA training set (n=177) first underwent univariate survival analysis by using the 'survival coxph function' in the R package to investigate the genes linked to patient prognosis and survival. Typically, a difference of P\<0.05 was considered to indicate a statistically significant difference. The significant genes were subsequently screened by multivariate Cox proportional hazards regression, using regional lymph nodes (N) and tumor size (T) as covariants for the model and P\<0.05 as threshold for significance. Prognostic genes recognized using the glmnet of R package (family='cox'; nλ=100; α=1) were then refined using lasso Cox regression ([@b39-or-44-03-0819]), which was appropriate for the regression analysis of high-dimensional data. By using the regularization coefficient of machine learning (λ, also known as penalty coefficient), the number of variables when the cross validation error is minimum was found. DESeq2 ([@b40-or-44-03-0819]) was then used for calculating DEGs that participated in energy metabolism by applying the thresholds of false discovery rate (FDR) \<0.05 and \|log~2~ fold change\|\>1. The R package cluster profile ([@b41-or-44-03-0819]) was subsequently used to perform enrichment analysis of the DEGs by turning them to ENTREZID. Afterwards, the ENTREZIDs were enriched using the enrich Kyoto Encyclopedia of Genes and Genomes pathways (KEGG) and the enrich gene ontology (GO) functions by applying the P\<0.05 threshold. Using the enrichment map software from Cytoscape (version 3.8.0; <http://cytoscape.org/>) ([@b42-or-44-03-0819]), a visualization of the enrichment results was then obtained. By applying the coefficients obtained from lasso Cox regression analysis and expression value of each gene, a specific risk signature was finally constructed, the formula of which was shown below:

Risk score=0.051 × IL1RL2 + 0.012 × FBLN7 + 0.01 × CA3 + 0.146 × PDE1B + 0.01 × SLURP1 + 0.002 × CILP + 0.011 × AQP7 + 0.003 × TPSB.

The risk score values of all patients in the TCGA training set were determined based on linear combination with the expression of signature-related genes weighted according to the corresponding regression coefficients. The regression coefficients from the training set were then applied into the GEO validation set for risk score calculation.

### Multiple regression analyzes, gene set enrichment analysis (GSEA) and gene ontology (GO) analysis

GO analysis was performed to annotate the major functions of the DEGs using the Database for Annotation, Visualization and Integrated Discovery online tool v6.8 (version 6.8; <http://david.ncifcrf.gov/>). The statistically different genes identified between high risk and low risk groups, which were classified according to the median risk score values, were using the GSEA v7.1 software (MSigDB; <http://software.broadinstitute.org/gsea/msigdb/index.jsp>) ([@b43-or-44-03-0819]). Multiple regression analyses were performed to determine the association between the clinical features and the risk score values, which were displayed as forest plots and nomograms.

### Statistical analysis

All cases were classified into high-risk or low-risk groups according to the median risk score value. Differences in disease-free survival (DFS) between the two groups were evaluated using Kaplan-Meier combined with a two-sided log-rank test. Differences in the pathological characteristics between the two groups were compared using χ^2^ test. Multivariate and univariate cox regression analyses were performed for identifying the independent prognosis factors. Lasso regression was used for narrowing the number of genes. ROC curve was used to test the sensitivity and specificity of risk score model and to calculate the cutoff value using Youden\'s index ([@b44-or-44-03-0819]). R or SPSS version 19.0 software (IBM Corp.) was used for all statistical analyses. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Molecular subtypes on the basis of different genes associated with energy metabolism

To examine the state of energy metabolism in TNBC, a total of 369 cases including available clinical data and RNA sequencing profiles were acquired from the GEO and TCGA databases. In addition, one separate gene set containing 594 genes that were associated with energy metabolism was also collected from the Reactome database. The NMF algorithm was applied for clustering the TNBC cases, where the best k number was calculated to be 4 based on silhouette, dispersion and cophenetic analyses ([Fig. 1A](#f1-or-44-03-0819){ref-type="fig"}). The expression levels of genes associated with energy metabolism across the four subtypes are displayed in [Fig. 1B](#f1-or-44-03-0819){ref-type="fig"}, where the expression profiles of some genes were shown to be heterogenous across the different subtypes. Prognosis among the patients within the four subtypes was subsequently examined. Subtype C2 exhibited the poorest prognosis, such that subtypes C1, C3 and C4 all exhibited markedly superior prognoses compared with those in the C2 subtype (log rank P=0.06; [Fig. 1C](#f1-or-44-03-0819){ref-type="fig"}).

Differences in the aforementioned four TNBC case clusters was measured. Firstly, associations of the TNBC mutation profiles with each of the four sub-classifications were examined using maftools v1.6.15 from R package. After the synonymous mutations were eliminated, the missense and nonsense gene mutations were obtained. The overall heterogeneity in mutation frequency among the different subtypes was found to be of statistical significance ([Fig. 1D](#f1-or-44-03-0819){ref-type="fig"}). Subsequently, differences in the clinicopathological characteristics, including age, TNM and stage, were compared among the four subtypes. The differences in the clinicopathological features among the four TNBC subtypes were not found to be statistically significant ([Table III](#tIII-or-44-03-0819){ref-type="table"}). In addition, samples from these 4 subtypes were analyzed using the TIMER method. The scores in terms of the three types of immune cells, including dendritic cells, macrophages and CD4 T cells were found to be higher in samples from the C2 subtype compared with those from the other subtypes ([Fig. 2](#f2-or-44-03-0819){ref-type="fig"}). These findings suggested that the immune microenvironment or the degree of immunocyte infiltration in TNBC was associated with patient prognosis. In addition, the expression profiles of genes associated with energy metabolism displayed close association with the clinical characteristics and patient prognosis in TNBC.

### Identification of the prognostic signature associated with energy metabolism for TNBC

To examine the relationship between the expression profiles of genes associated with energy metabolism and the TNBC prognosis, DESeq2 was used for calculating DEGs that participated in energy metabolism between samples from the C2 subtype, which had the poorest prognosis and those in the C1, C3 or C4 subtypes, by applying the thresholds of FDR \<0.05 and \|log~2~ fold change\|\>1. Data shown in [Fig. 3](#f3-or-44-03-0819){ref-type="fig"} and [Table IV](#tIV-or-44-03-0819){ref-type="table"} suggested that a total of 1941 DEGs were identified between the subtype C2 samples and those in the C1, C3 and C4 subtypes. The R package cluster profile was subsequently used to perform enrichment analysis of these 1941 DEGs. KEGG pathway enrichment and GO enrichment analysis results appeared to show that these genes were mostly enriched in biological functions and pathways associated with 'calcium homeostasis', 'angiogenesis', the metabolism of molecules including glutathione, arachidonic acid, drugs and xenobiotics and 'positive cell migration regulation' ([Fig. 4](#f4-or-44-03-0819){ref-type="fig"}).

Since patient prognosis was found to be closely associated with the energy metabolism state, a signature associated with energy metabolism was therefore proposed to predict patient prognosis. Univariate Cox regression analysis suggested that 102 of these DEGs showed significant association with the DFS of patients in the training set (top 20 DEGs shown in [Table V](#tV-or-44-03-0819){ref-type="table"}). Subsequently, the univariate Cox proportional hazards regression model was performed to analyze the age, TNM stages, stage, age and survival data. Differences in stage, lymph node and tumor size were found to be statistically significant in predicting prognosis ([Fig. 5](#f5-or-44-03-0819){ref-type="fig"}). Multivariate Cox proportional hazards regression model was utilized to select for the genes associated with energy metabolism that displayed the highest prognostic significance, using stage, N and T as covariants. A total of 14 genes associated with energy metabolism that were specific to prognosis were mined and narrowed by lasso regression to reduce the number of genes selected for the construction of the prognostic signature. Typically, the lasso algorithm uses the biased estimate to process multicollinearity data, to estimate and screen variables and to solve the multicollinearity problem encountered during regression analysis. In the present study, the glmnet function of R package was used to perform the lasso regression analysis. For every independent parameter, a variation trajectory was evaluated ([Fig. 6A](#f6-or-44-03-0819){ref-type="fig"}) The coefficients of the 14 genes were revealed to be \~0 as the λ gradually increased. Additionally, a model was constructed using a three-fold cross-validation. [Fig. 6B](#f6-or-44-03-0819){ref-type="fig"} presents the confidence interval for every λ, which suggested that λ=0.0283271 would result in the best model. Consequently, the signature with λ=0.0283271 was applied to be the eventual signature, which involves eight genes associated with energy metabolism.

### The eight-gene based signature shows potential in predicting prognosis for TNBC

The risk score values for the samples in the training set were first calculated, following which the samples were divided into high-risk and low-risk groups according to the risk score values and set at a threshold of 1.351149 according to the 3-year area under the curve (AUC) after Youden\'s index analysis. [Fig. 7](#f7-or-44-03-0819){ref-type="fig"} displays the efficiency of the constructed eight-gene signature in classifying samples in the TCGA training set. showed that, for the samples from the deceased group, the survival time was markedly reduced as the patient risk score value increased ([Fig. 7A](#f7-or-44-03-0819){ref-type="fig"}). In addition, the high-risk group was found to be associated with the increased number of deceased samples ([Fig. 7A](#f7-or-44-03-0819){ref-type="fig"}). The increased levels of the eight genes associated with energy metabolism also appeared to be risk factors, since the risk score values were found to be increased when the expression levels of these eight genes were increased ([Fig. 7A](#f7-or-44-03-0819){ref-type="fig"}). According to the ROC curves, the 1-, 3- and 5-year AUC were calculated to be 0.89, 0.80 and 0.80, respectively ([Fig. 7B](#f7-or-44-03-0819){ref-type="fig"}). After the patients were divided into low-risk and high-risk groups, the difference in DFS between the two groups was revealed to be statistically significant (HR=3.78; P\<0.0001; [Fig. 7C](#f7-or-44-03-0819){ref-type="fig"}).

To determine the reliability of the constructed eight-gene signature, an identical model used for the TCGA training set samples was performed on the two GEO test sets. For the GSE21653 dataset, according to the ROC analysis, a 1-year AUC of 0.65 was found, although interpretation was restricted by the limited follow-up time of the samples ([Fig. 8A](#f8-or-44-03-0819){ref-type="fig"}). Subsequently, a total of 70 cases were divided into the low-risk group, whereas 15 were allocated into the high-risk group using a threshold of 1.475448 according to the 1-year AUC, where a statistically significant difference was found between the two groups (P=0.0011; [Fig. 8B](#f8-or-44-03-0819){ref-type="fig"}). For the GSE58812 dataset, ROC analysis revealed the 1-year AUC to be 0.63, but interpretation was restricted by the limited follow-up time of the samples ([Fig. 8C](#f8-or-44-03-0819){ref-type="fig"}). According to [Fig. 8D](#f8-or-44-03-0819){ref-type="fig"}, a total of 98 cases were allocated into the low-risk group, whereas 8 were assigned into the high-risk group using a threshold of 32.77999 according to the 1-year AUC, where there was a statistically significant difference between the two groups (P=0.0019). The threshold was found to be large, possibly due to the larger variation in the GSE58812 dataset. For the overall expression levels of the two GSE datasets, the calculated risk scores differed drastically. In conclusion, the signature constructed based on these eight genes showed high accuracy in predicting prognosis for patients in both internal and external TNBC datasets.

Compared with recent studies that also investigated the prognostic models for TNBC ([@b45-or-44-03-0819]--[@b47-or-44-03-0819]), that present study also calculated the risk scores of each sample obtained from the TCGA database using the method reported in the present study and those from the previous studies, where ROC analysis was performed for each model. The samples were then divided into high-risk and low-risk groups using the median risk score, following which the difference in the prognosis of patients between the high-risk and low risk groups were compared. It was found that the signature derived from the present study was superior compared with the other models from the recent studies in terms of prognostic prediction ([Fig. S1](#SD1-or-44-03-0819){ref-type="supplementary-material"}).

### The signature constructed based on genes associated with energy metabolism is superior compared with other clinical features in predicting survival of patients with TNBC

The risk score values were utilized in combination with other clinicopathological features to construct a nomogram model for the TNBC cases. Nomogram is a method for effectively and intuitively presenting the results of a risk model, which can be adopted conveniently for predicting patient outcome ([@b48-or-44-03-0819]). Specifically, length of the straight line within the nomogram indicates the influence of the various parameters on the significance of patient outcome. In the present study, a nomogram was constructed by integrating age, risk scores, stage, N and T ([Fig. 9A](#f9-or-44-03-0819){ref-type="fig"}). The risk score features were revealed to be associated with survival prediction. This predictive efficiency was assessed further using the ROC analysis to calculate the AUC of the nomogram scores, which was obtained using the 'predict' function from the R package. According to [Fig. 9B](#f9-or-44-03-0819){ref-type="fig"}, the 1-, 3- and 5-year AUC of nomogram were calculated to be 0.95, 0.93 and 0.92, respectively. In addition, the constructed nomogram model displayed consistent predictive capacity compared with that of the ideal model (dotted line) for predicting the 3-year survival of patients with TNBC ([Fig. 9C](#f9-or-44-03-0819){ref-type="fig"}). Finally, a forest plot was constructed based on the risk score values and the clinicopathological features. The HRs of the risk score value was calculated to be \~3.848, as observed from the forest plots constructed based on risk score values, stage, N, T and age (P\<0.001; [Fig. 9D](#f9-or-44-03-0819){ref-type="fig"}), suggesting that the signature constructed based on the expression profiles of the eight genes associated with energy metabolism exhibited adequate capacity in predicting prognosis in patients with TNBC.

### Differences in pathways involved in GSEA between the low and high-risk groups

GSEA was used for analyzing the markedly enriched pathways between the low-risk and high-risk groups according to the TCGA training set samples, where 20 markedly enriched pathways were acquired in total. Genes associated with the high-risk group were particularly enriched in the 'MAPK signal transduction pathway', 'focal adhesion', 'hedgehog signaling', 'cardiomyopathy' and 'ECM receptor interaction', whilst those associated with the low-risk group were involved in 'mismatch repair' and 'propanoate metabolism' ([Fig. 10](#f10-or-44-03-0819){ref-type="fig"}; [Table VI](#tVI-or-44-03-0819){ref-type="table"}).

Discussion
==========

TNBC accounts for \~15-20% of all BC cases, which is particularly prevalent among younger women aged \<40 years. TNBC is a complex disease with substantial heterogeneity, which is associated with inferior prognosis compared with that in other BC subtypes. Currently, treatments for TNBC mainly include surgery combined with adjuvant chemotherapy for early stage disease and chemotherapy for advanced stage disease. However, surgical resection remain ineffective due to the localized invasion of cancer cells to adjacent tissues or the development of distant metastasis ([@b49-or-44-03-0819],[@b50-or-44-03-0819]). Additionally, effects exerted by chemotherapy may be diminished due to tumor heterogeneity ([@b51-or-44-03-0819],[@b52-or-44-03-0819]). Therefore, identifying novel candidate biomarkers for the prognostic prediction of TNBC is important for finding novel treatment targets for this disease and to accurately manage patients potentially developing complete response from adjuvant treatment. In the present study, a gene expression signature was explored as potential approach for the prognostic prediction of TNBC.

A number of previous studies have classified TNBC subtypes using genomic profiling, which allows for the specific classification and accurate prediction of TNBC outcomes. Using the TIMER method, it was found that the scores for the three immune cell types, specifically dendritic cells, macrophages and CD4 cells, were higher in the samples of the C2 subtype compared with those of other subtypes, suggesting that the immune microenvironment or the degree of immunocyte infiltration in TNBC was associated with patient prognosis. Several molecular markers, including O6-methylguanine DNA methyltransferase, isocitrate dehydrogenase, epidermal growth factor receptor and phosphatase and tensin homolog, were previous examined among patients with TNBC, facilitating targeted and personalized anti-TNBC therapy. Fumagalli C *et al* ([@b8-or-44-03-0819]) previously found that patients with TNBC carrying a silencing mutation in the O6-methylguanine DNA methyltransferase gene are associated with an increase in the susceptibility for alkylating agents. Wang *et al* ([@b10-or-44-03-0819]) found that epidermal growth factor induced the expression of Fascin-1 through the activation of MAPK, which lead to poorer relapse-free survival and overall survival for patients with TNBC. However, since TNBC is associated with poor prognosis, identification of novel molecular biomarkers and development of treatment strategies are urgently sorted for unravelling the possible mechanisms of TNBC progression or improving patient prognosis.

Accumulating evidence suggested that the aberrant metabolism can serve as a hallmark for cancer cells. In recent years, significant research effort has been made on investigating the difference in energy metabolism between tumor and normal cells ([@b53-or-44-03-0819]--[@b55-or-44-03-0819]). Recent studies on TNBC revealed that a number of catabolic pathways can participate in energy metabolism, including fatty acid metabolism, OXPHOS and glycolysis ([@b28-or-44-03-0819],[@b56-or-44-03-0819],[@b57-or-44-03-0819]). Consequently, it is of great significance to screen for new genes associated with energy metabolism that are specific to prognosis, to accurately predict the prognosis for patients, develop therapeutic strategies and identify patients with a high risk of postoperative relapse. In the present study, tumor size (T), nodal status (N), age and TNM stages were applied as the prognostic predictors to select for genes associated with energy metabolism. For TNBC, these are classical prognostic predictors that are universally acknowledged ([@b58-or-44-03-0819],[@b59-or-44-03-0819]). Consistent with this, the present study found the differences in stage, N and T to be statistically significant in predicting prognosis, showing them to be good prognostic predictors.

In the present study, the relationship between energy metabolic state in the tumor microenvironment and the prognostic significance among patients with TNBC was determined based on RNA sequencing data. Use of profiling data of genes associated with energy metabolism allowed for the delineation of molecular and clinical characteristics among patients with TNBC. In addition, a signature was developed for patient stratification into low-risk or high-risk groups for predicting poor prognosis. Univariate Cox model was considered to be insufficient in selecting the variables based on dimensional data. Therefore, it was applied to first screen for the genes associated with DFS, following which an elastic net Cox regression model was used for enhancing the prognostic prediction performance of the indices. The eight genes acquired exerted cumulative effects on predicting patient survival. This signature associated with energy metabolism could be used as an effective indicator for prognosis prediction and patient stratification for future treatments targeting energy metabolism.

Based on the present study, five of the eight genes in the signature had been previously recognized to participate in TNBC pathogenesis, immune microenvironment, progression and malignant transformation, which were interleukin-1 receptor-like 2, carbonic anhydrase 3, phosphodiesterase 1B, secreted Ly-6/uPAR-related protein and aquaporin 7 ([@b60-or-44-03-0819]--[@b63-or-44-03-0819]). These five genes showed marked correlation with the prognosis and survival of patients. These results suggested that the bioinformatic mining results were reliable and accurate. However, it remains unclear regarding the association between the other genes and TNBC physiology, which require further study. Fibulin 7 has been previously reported to participate in the regulation of aberrant neovascularization by modulating the angiopoietin-1/angiopoietin-2-Tie2 axis ([@b64-or-44-03-0819]). A previous study has shown that the cartilage intermediate layer protein gene is differentially expressed in differentiated thyroid carcinomas in comparison with normal thyroid tissues ([@b65-or-44-03-0819]). By contrast, tryptase-β2 (TPSB) was documented as a major neutral protease present in mast cells that participate in tumor-associated immunity and can serve as a prognostic marker for several types of cancer ([@b66-or-44-03-0819],[@b67-or-44-03-0819]). TPSB has also been demonstrated to upregulate vascular endothelial growth factor production in the tumor microenvironment via the protease-activated receptors-2, ERK1/2 and p38 MAPK signaling pathways ([@b68-or-44-03-0819]).

In conclusion, the expression profiles of genes associated with energy metabolism and their prognostic significance in TNBC was revealed in the present study. A signature associated with energy metabolism was subsequently constructed, allowing for the classification of patients with TNBC into high-risk or low-risk groups in terms of survival. However, further study is required, since the predictive capacity of the eight-gene signature constructed in the present study need to be tested in a clinical setting. Results in the present study can shed new light on the relationship between the metabolic state and TNBC pathophysiology and potentially aid in the development of novel TNBC treatment strategies targeting energy metabolism.
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Identification of the molecular subtypes of TNBC by NMF analysis. (A) Plots showing the NMF cluster results. Colour scale represents the P-values of the cluster results, where red indicates high probability of two samples belonging to the same cluster and blue indicates low probability of two samples in the different cluster. (B) Expression levels of genes associated with energy metabolism across the four subtypes were tested. Colour scale represents the gene expression levels, where red indicates upregulation and green indicates downregulation. Identification of the molecular subtypes of TNBC by NMF analysis. (C) The difference in prognosis among the four subgroups. (D) The overall heterogeneity in mutation frequency among the four subtypes. Colour scale represents the expression levels of each gene, where blue indicates upregulation and grey indicates downregulation. NMF, non-negative factorization; TNBC, triple-negative breast cancer; HR, hazard ratio.

![](OR-44-03-0819-g00)

![](OR-44-03-0819-g01)
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![Calculation of DEGs associated with energy metabolism between samples of the C2 subtype and those of the C1/C3/C4 subtypes. (A) Volcano plots of DEGs comparing C1 and C2. (B) Volcano plots of DEGs comparing C3 and C2. (C) Volcano plots of DEGs comparing C4 and C2. (D) The upset intersection diagram showing the three types of DEGs between C1/C3/C4 and C2. DEGs, differentially expressed genes; FDR, false discovery rate.](OR-44-03-0819-g03){#f3-or-44-03-0819}

![Functional analysis of the DEGs associated with energy metabolism. (A) Top 20 gene ontology terms enriched by the 1941 DEGs. (B) Kyoto Encyclopedia of Genes and Genomes pathways enriched by the 1941 DEGs. DEGs, differentially expressed genes.](OR-44-03-0819-g04){#f4-or-44-03-0819}

![Analysis of tumor size, lymph node, TNM stage and age as prognostic indicators for triple-negative breast cancer. Comparison of patient prognosis according to (A) tumor size, (B) lymph node, (C) TNM stage and (D) age.](OR-44-03-0819-g05){#f5-or-44-03-0819}

![Identifying the prognosis signature associated with energy metabolism for triple-negative breast cancer using lasso. (A) Coefficients calculated for each lambda. Each line represents a gene confidence value. (B) The changing trajectory of each independent variable. The horizontal axis represents the log value of the independent variable λ, whilst the vertical axis represents the partial likelihood deviance of the log value of each independent variable λ.](OR-44-03-0819-g06){#f6-or-44-03-0819}

![The classification effect of the eight-gene signature associated with energy metabolism in the TCGA training set. (A) The relationship between the risk score, survival time, survival status and the expression levels of the eight genes derived from the TCGA training set. Colour scale represents the expression levels of the eight genes, where red indicates upregulation and green indicates downregulation. (B) ROC curves of the eight-gene signature in triple-negative breast cancer samples obtained from the TCGA training set. (C) Analysis of prognosis following classification into the high risk and low-risk groups according to the eight-gene signature. TCGA, The cancer genome atlas; ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; IL1RL2, interleukin-1 receptor-like 2; CA3, carbonic anhydrase 3; PDE1B, phosphodiesterase 1B; SLURP, secreted Ly-6/uPAR-related protein; AQP7, aquaporin 7; TPSB, tryptase-β2; FBLN7, fibulin 7; CILP, cartilage intermediate layer protein.](OR-44-03-0819-g07){#f7-or-44-03-0819}

![The classification effect of the eight-gene signature associated with energy metabolism on the GEO test set. (A) ROC curves of the eight-gene signature in TNBC samples obtained from the GSE21653 test set. (B) Analysis of the prognosis into the high risk and low-risk groups according to the eight-gene signature in the GSE21653 test set. (C) ROC curves of the eight-gene signature in TNBC samples obtained from the GSE51882 test set. (D) Analysis of the prognosis into the high risk and low-risk groups according to the eight-gene signature in the GSE51882 test set. TNBC, triple-negative breast cancer; HR, hazard ratio; CI, confidence ratio; ROC, receiver operating characteristic; AUC, area under the curve.](OR-44-03-0819-g08){#f8-or-44-03-0819}

###### 

The eight-gene signature constructed based on genes associated with energy metabolism is a more accurate prognostic indicator for TNBC compared with other clinicopathological features. (A) The nomogram model constructed by combining the T, N, TNM stage, age with risk scores for TNBC samples. 'Points' and 'total points' represents the reference index for the score of nomogram. (B) ROC curves of the nomogram scores in the TNBC samples. (C) The calibration plots for predicting 3-year overall survival of patients with TNBC. nomogram-predicted probability of survival is plotted on the x-axis; actual survival is plotted on the y-axis. The eight-gene signature constructed based on genes associated with energy metabolism is a more accurate prognostic indicator for TNBC compared with other clinicopathological features. (D) The forest plot constructed based on the risk score values and the clinical features. HR, hazard ratio; TNBC, triple negative breast cancer.
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###### 

Functional analysis of the eight-gene signature. (A) Visualization of the GSEA enrichment results, calculated based on the median values of the risk scores using the enrichment map software from Cytoscape. The red region represents the enriched pathways in the high-risk group, whilst the blue region represents the enriched pathways in the low-risk group. The sizes of the red/blue dots indicates the score of enrichment, the higher the score of enrichment, the larger the dot sizes. Functional analysis of the eight-gene signature. Enrichment plots for (B) nucleotide excision pair, (C) proparoate metabolism, (D) MAPK signaling pathway, (E) ECM receptor interaction, (F) hedgehog signaling pathway and (G), hypertrophic cardiomyopathy. GSEA, gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes pathways; ECM, extracellular matrix.
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###### 

Gene sets related to energy metabolism extracted from the Reactome database.

  Metabolic pathways from the Reactome              Pathway ID          Gene count
  ------------------------------------------------- ------------------- ------------
  Biological oxidations                             R-HSA-211859        221
  Metabolism of carbohydrates                       R-HSA-71387         292
  Mitochondrial fatty acid beta-oxidation           R-HSA-77289         38
  Glycogen synthesis                                R-HSA-3322077       16
  Glycogen metabolism                               R-HSA-8982491       27
  Glucose metabolism                                R-HSA-70326         92
  Glycogen breakdown (glycogenolysis)               R-HSA-70221         15
  Glycolysis                                        R-HSA-70171         72
  Pyruvate metabolism                               R-HSA-70268         31
  Pyruvate metabolism and citric acid (TCA) cycle   R-HSA-71406         55
  Citric acid cycle (TCA cycle)                     R-HSA-71403         22
  Sum                                               881 (unique: 594)   

###### 

Clinicopathological features of the samples after series data pre-processing.

  Characteristic    TCGA datasets (n=177)   GSE21653 (n=85)   GSE58812 (n=107)
  ----------------- ----------------------- ----------------- ------------------
  Age (years)                                                 
    ≤60             118                     50                64
    \>60            59                      35                43
  Survival status                                             
    Living          150                     58                78
    Deceased        27                      27                29
  Gender                                                      
    Female          177                     85                107
    Male            0                       0                 0
  T                                                           
    T1              45                      16                --
    T2              110                     45                --
    T3              14                      23                --
    T4              7                       0                 --
  N                                                           
    N0              105                     51                --
    N1              45                      33                --
    N2              15                      0                 --
    N3              10                      0                 --
  M                                                           
    M0              154                     --                --
    M1              1                       --                --
    MX              21                      --                --
  Tumor stage                                                 
    Stage I         31                      --                --
    Stage II        109                     --                --
    Stage III       32                      --                --

TCGA, the cancer genome atlas.

###### 

Clinicopathological features among the four triple-negative breast cancer subtypes.

  Clinical features   C1   C2   C3   C4   P-value
  ------------------- ---- ---- ---- ---- ---------
  Outcome                                 0.130
    Alive             28   20   48   54   
    Deceased          6    8    5    8    
  T                                       0.078
    T1                8    10   16   11   
    T2                20   14   30   46   
    T3                3    1    6    4    
    T4                3    3    1    0    
  N                                       0.058
    N0                14   19   33   39   
    N1                8    4    15   18   
    N2                6    1    5    3    
    N3                4    4    0    2    
  Stage                                   0.061
    I                 5    8    10   8    
    II                17   12   35   45   
    III               11   8    7    6    
  Gender                                  --
    Female            34   28   53   62   
    Male              0    0    0    0    
  Age                                     0.686
    ≤60               20   19   35   44   
    \>60              14   9    18   18   

###### 

Comparison of differentially expressed genes in samples from the C2 subtype with the C1, C3 and C4 subtypes.

  Type       C2/C1   C2/C3   C2/C4
  ---------- ------- ------- -------
  PCG_Up     700     304     448
  PCG_Down   628     186     233
  PCG_All    1328    490     681

PCG, protein coding gene.

###### 

Top 20 DEGs that showed significant correlation with the disease-free survival of patients in the training set by analysis of univariate Cox regression.

  Symbol      P-value         Hazard ratio   Low 95% CI   High 95% CI
  ----------- --------------- -------------- ------------ -------------
  *KRTDAP*    1.48×10^−05^    1.009          1.005        1.013
  *PLAC9*     4.89×10^−05^    1.021          1.011        1.031
  *CD248*     6.91×10^−05^    1.004          1.002        1.006
  *SPRR2G*    2.55×10^−04^    1.035          1.016        1.055
  *EFNB1*     2.82×10^−04^    1.016          1.007        1.025
  *SPON2*     3.17×10^−04^    1.006          1.003        1.010
  *PTGDS*     4.44×10^−04^    1.002          1.001        1.003
  *CA3*       5.86×10^−04^    1.010          1.004        1.015
  *PTGER1*    6.55×10^−04^    1.747          1.267        2.407
  *CILP*      6.66×10^−04^    1.005          1.002        1.007
  *COL16A1*   7.28×10^−04^    1.009          1.004        1.014
  *CNFN*      7.99×10^−04^    1.015          1.006        1.024
  *PDE1B*     1.12×10^−03^    1.246          1.091        1.422
  *ACVRL1*    1.170×10^−03^   1.055          1.022        1.090
  *COL5A3*    1.39×10^−03^    1.009          1.003        1.014
  *PYGM*      1.40×10^−03^    1.914          1.285        2.850
  *MYL3*      1.55×10^−03^    1.490          1.164        1.907
  *DCSTAMP*   1.63×10^−03^    1.292          1.102        1.515
  *RARRES2*   1.68×10^−03^    1.003          1.001        1.005
  *C1QTNF7*   1.68×10^−03^    1.297          1.103        1.525

CI, confidence interval.

###### 

KEGG pathway of genes associated with the high-risk groupand those associated with the low-risk group.

  Name                                            Size   Es^[a](#tfn4-or-44-03-0819){ref-type="table-fn"}^   Nes      Nom P-value   FDR q-value
  ----------------------------------------------- ------ --------------------------------------------------- -------- ------------- -------------
  KEGG_dilated_cardiomyopathy                     90     0.473                                               1.816    0.003         0.475
  KEGG_calcium_signaling_pathway                  176    0.348                                               1.574    0.003         0.489
  KEGG_hypertrophic_cardiomyopathy_hcm            83     0.448                                               1.735    0.008         0.318
  KEGG_ecm_receptor_interaction                   84     0.553                                               1.799    0.010         0.279
  KEGG_notch_signaling_pathway                    47     0.424                                               1.618    0.013         0.561
  KEGG_vascular_smooth_muscle_contraction         115    0.379                                               1.586    0.023         0.546
  KEGG_mapk_signaling_pathway                     265    0.287                                               1.357    0.045         0.771
  KEGG_protein_export                             23     −0.661                                              −1.902   0.000         0.169
  KEGG_biosynthesis_of_unsaturated_fatty_acids    22     −0.643                                              −1.866   0.002         0.123
  KEGG_n\_glycan_biosynthesis                     46     −0.504                                              −1.764   0.006         0.180
  KEGG_steroid_biosynthesis                       16     −0.729                                              −1.804   0.007         0.163
  KEGG_glyoxylate_and_dicarboxylate_metabolism    16     −0.627                                              −1.745   0.009         0.143
  KEGG_one_carbon_pool_by_folate                  17     −0.568                                              −1.603   0.012         0.338
  KEGG_terpenoid_backbone_biosynthesis            15     −0.663                                              −1.714   0.013         0.163
  KEGG_pentose_and_glucuronate_interconversions   27     −0.609                                              −1.593   0.026         0.325
  KEGG_proteasome                                 44     −0.617                                              −1.747   0.034         0.168
  KEGG_nucleotide_excision_repair                 44     −0.480                                              −1.562   0.039         0.331
  KEGG_pantothenate_and_coa_biosynthesis          16     −0.552                                              −1.556   0.040         0.317
  KEGG_propanoate_metabolism                      32     −0.511                                              −1.545   0.046         0.314
  KEGG_citrate_cycle_TCA_cycle                    30     −0.564                                              −1.578   0.049         0.325

Es\>0, high risk and Es\<0, low risk. KEGG, Kyoto Encyclopedia of Genes and Genomes pathways; Es, enrichment score; Nes, normalized enrichment score; Nom, normalized; FDR, false discovery rate.
